1. Food and Drug Administration (FDA). Assessing the effects of food on drugs in INDs and NDAs-clinical pharmacology considerations guidance for industry. Guid Doc [Internet]. 2019. Available from https://www.fda.gov/media/121313/download. Accessed 24/10/2020.
2. European Medicines Agency (EMA). Guideline on the investigation of drug interactions. Guid Doc [Internet]. 2012;44:1–59. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/07/WC500129606.pdf. Accessed 24/10/2020.
3. Guimarães M, Statelova M, Holm R, Reppas C, Symilllides M, Vertzoni M, Fotaki N. Biopharmaceutical considerations in paediatrics with a view to the evaluation of orally administered drug products – a PEARRL review. J Pharm Pharmacol. 2019;71(4):603–42.
4. Statelova M, Goumas K, Fotaki N, Holm R, Symillides M, Reppas C, Vertzoni M. On the design of food effect studies in adults for extrapolating oral drug absorption data to infants: an exploratory study highlighting the importance of infant food. AAPS J. 2020;22(6):1–11.
5. World Health Organization (WHO). Paediatric age categories to be used in differentiating between listing on a model essential medicines list for children. Position Pap. 2007;1–5.